TIBSOVO 250 MG COMPRIMIDOS RECUBIERTOS CON PELICULA

( ARTG ) Cholangiocarcinoma,TIBSOVO is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an isocitrate dehydrogenase-1 (IDH1) R132 mutation after at‍‍‍‍‍‍​​​‍​​​​​​ least one prior line of systemic therapy.,Acute myeloid leukaemia,TIBSOVO is indicated for the treatment of acute myeloid leukaemia (AML) that carries an IDH1 R132 mutation:, as monotherapy, or in combination with azacitidine, in newly diagnosed patients who are not eligible to receive intensive induction chemotherapy; or, as monotherapy in patients whose AML is relapsed and/or refractory to prior therapy.